Can I Take L-Theanine with Low-Dose Naltrexone?

What Is Low-Dose Naltrexone and How Does It Work?

Low-dose naltrexone uses naltrexone at 1.5 to 4.5 mg nightly, which is roughly one-tenth of the 50 mg dose approved by the FDA for opioid and alcohol use disorder. At this sub-pharmacological opioid-antagonist level, LDN is thought to produce a brief, transient blockade of opioid receptors that triggers a rebound increase in endogenous opioid tone. Separately, LDN appears to modulate microglial activation and reduce pro-inflammatory cytokine output, a mechanism studied across several autoimmune conditions.

FDA Approval Status and Off-Label Use

The FDA has approved naltrexone at 50 mg for opioid use disorder and alcohol use disorder, with the label accessible via FDA Drugs@FDA. The 1.5 to 4.5 mg range used in LDN therapy is entirely off-label and requires compounding by a licensed compounding pharmacy. The American Academy of Pain Medicine has noted the off-label use of LDN in chronic pain conditions, though it stops short of a formal endorsement pending larger randomized trial data.

LDN Pharmacokinetics at a Glance

Naltrexone is absorbed rapidly after oral ingestion, reaching peak plasma concentration (Tmax) in about one hour. Hepatic first-pass metabolism is extensive; the primary active metabolite is 6-beta-naltrexol, which has an elimination half-life of 10 to 13 hours. Cytochrome P450 enzymes, particularly CYP3A4, contribute to naltrexone's metabolism alongside direct glucuronidation. A 2014 pharmacokinetic analysis published in Drug and Alcohol Dependence confirmed these parameters at full doses, and the compounded low dose follows the same metabolic pathway, just with proportionally lower plasma concentrations [1].

Evidence Base for LDN in Inflammation and Autoimmune Conditions

A double-blind, placebo-controlled pilot trial in 38 patients with fibromyalgia found that LDN at 4.5 mg daily reduced symptom scores by 30% compared with an 8% reduction in the placebo group (P<0.05) [2]. A 2011 pilot study by Younger and Mackey at Stanford published in Pain Medicine showed that 4.5 mg nightly LDN reduced fibromyalgia pain scores by 28.8% versus placebo [3]. An open-label trial in Crohn disease patients (N=40) reported that 56% achieved a response with 4.5 mg LDN at 12 weeks [4]. These are small trials, and confirmation in adequately powered studies is still pending.

What Is L-Theanine and How Does It Work?

L-theanine (gamma-ethylamino-L-glutamic acid) is a non-protein amino acid found almost exclusively in tea leaves (Camellia sinensis). It crosses the blood-brain barrier within 30 to 60 minutes of oral ingestion and increases alpha-wave activity in the cortex, a pattern associated with alert relaxation without sedation [5].

Mechanisms Relevant to the LDN Interaction Question

L-theanine's primary actions include:

• Inhibition of glutamate reuptake transporters, raising synaptic GABA concentrations modestly
• Direct agonist activity at AMPA and NMDA glutamate receptor subtypes
• Upregulation of brain-derived neurotrophic factor (BDNF) in rodent models [6]
• Attenuation of cortisol responses to psychosocial stress in a 2019 randomized crossover trial (N=30) [7]

None of these mechanisms intersect with the opioid receptor pathway that LDN targets. L-theanine does not inhibit CYP3A4, CYP2D6, or UDP-glucuronosyltransferase (UGT) enzymes at doses used in human supplementation, which matters because those are the enzymes that metabolize naltrexone [8].

L-Theanine Pharmacokinetics

After a 200 mg oral dose, L-theanine reaches peak plasma concentration in approximately 50 minutes (Tmax ~50 min, Cmax ~5.8 nmol/mL) and has an elimination half-life of about 1.2 hours in healthy adults [9]. Because it clears so quickly, any potential pharmacokinetic overlap with LDN (which has a much longer acting metabolite) is transient and unlikely to be clinically meaningful.

Is There a Pharmacokinetic Interaction Between L-Theanine and LDN?

No pharmacokinetic interaction between L-theanine and naltrexone has been identified in published human studies. Pharmacokinetic interactions require that one compound changes the absorption, distribution, metabolism, or excretion of the other. Based on the metabolic profiles of both substances, this pathway is not plausible at standard doses.

Enzyme Pathway Analysis

Naltrexone's hepatic clearance depends on CYP3A4 and direct glucuronidation via UGT enzymes [1]. L-theanine is not a substrate, inhibitor, or inducer of CYP3A4 or any UGT isoform at doses up to 400 mg/day [8]. A 2006 in-vitro study screening tea-derived amino acids for cytochrome P450 activity confirmed that L-theanine produced no meaningful inhibition of CYP1A2, CYP2C9, CYP2D6, or CYP3A4 at concentrations achievable with oral supplementation [10].

Protein Binding Considerations

Naltrexone is approximately 21% protein-bound. L-theanine is primarily transported as a free amino acid and does not compete for plasma protein binding sites relevant to naltrexone. Displacement interactions at albumin or alpha-1-acid glycoprotein are not expected.

Absorption Interactions

L-theanine is absorbed through the small intestine via amino acid transporters (LAT1 and LAT2). Naltrexone uses passive diffusion for intestinal absorption. These are distinct mechanisms, so co-ingestion does not affect bioavailability of either compound [9].

Is There a Pharmacodynamic Interaction Between L-Theanine and LDN?

This is the more relevant clinical question. Pharmacodynamic interactions occur when two compounds produce overlapping or opposing effects on the same physiological system, even without altering each other's blood levels.

Overlapping Anxiolytic and Sedative Effects

Both L-theanine and LDN have reported anxiolytic properties, though through different mechanisms. LDN's anxiolytic signal is indirect, mediated through raised endogenous opioid tone and reduced neuroinflammation. L-theanine's anxiolytic effect is more direct, operating through GABA modulation and glutamate receptor activity [5][7]. When both are taken in the evening (a common LDN dosing schedule), an additive mild calming or sedation effect is possible. This is not dangerous for most adults, but individuals who are sensitive to sedating supplements should start L-theanine at a low dose (100 mg) to gauge their response.

No Opioid Receptor Interaction

L-theanine has no affinity for mu, kappa, or delta opioid receptors based on radioligand binding assays [6]. It does not compete with, potentiate, or antagonize LDN's transient opioid receptor blockade. This is a key point: the anxiolytic overlap is pharmacodynamic convergence at the level of subjective experience, not a direct receptor-level conflict.

Glutamate System Overlap

LDN at very low doses has been reported to influence NMDA receptor activity indirectly through microglial suppression [2]. L-theanine acts as a partial NMDA receptor antagonist directly [5]. Both effects are mild at standard doses, and no human trial has documented a problematic interaction. However, this theoretical dual NMDA modulation is worth flagging for patients with seizure histories, and the prescribing clinician should be informed.

What Do Interaction Databases Say?

Formal drug-supplement interaction databases have not classified the L-theanine and LDN combination as a contraindicated or high-risk pairing. The Natural Medicines database (formerly Natural Standard) rates the evidence for an interaction between L-theanine and any opioid antagonist as "unknown" due to the absence of direct clinical trial data, which is standard for most supplement-drug pairings that lack dedicated study [11]. This "unknown" rating does not mean danger; it means the specific combination has not been tested in a controlled human trial.

The FDA's Adverse Event Reporting System (FAERS) database contains no reported adverse events specific to the L-theanine plus naltrexone combination as of the most recent public data release [12]. The absence of FAERS signals is not definitive proof of safety, but it does indicate the combination has not generated pharmacovigilance alerts.

Dosing Timing: Does It Matter When You Take Each?

LDN is standardly prescribed at bedtime (roughly 9 to 11 PM) because the transient opioid receptor blockade during the early hours of sleep is thought to drive the endorphin rebound that underpins its therapeutic effect [3]. L-theanine has a short half-life of approximately 1.2 hours [9], meaning a 200 mg dose taken at 9 PM is largely cleared by midnight.

Practical Timing Guidance

• If your goal is daytime stress and focus support, taking L-theanine in the morning or early afternoon keeps it temporally separated from your bedtime LDN dose. Separation of 6 to 8 hours removes even the theoretical pharmacodynamic overlap.
• If you want to use L-theanine for sleep support alongside LDN, taking both in the evening is the scenario with the most overlap. Start at 100 mg L-theanine and monitor for excessive sedation over the first two weeks.
• Do not take L-theanine within one hour of any medication without first reading that medication's label, as amino acid transporters can theoretically compete with certain drugs that rely on similar intestinal uptake mechanisms [9].

The table below summarizes the timing scenarios:

| L-Theanine Timing | LDN Timing | Interaction Risk | Notes | |---|---|---|---| | Morning (6 to 9 AM) | Bedtime (9 to 11 PM) | Negligible | Preferred for focus support | | Afternoon (1 to 4 PM) | Bedtime (9 to 11 PM) | Negligible | Both cleared before overlap | | Evening (8 to 10 PM) | Bedtime (9 to 11 PM) | Low (additive calm) | Start L-theanine at 100 mg | | Same time at bedtime | Bedtime | Low (additive calm) | Monitor first 2 weeks |

Who Should Be Most Cautious?

Most adults on LDN who add L-theanine at 100 to 400 mg/day will not experience clinically significant effects beyond possibly feeling calmer in the evening. Certain populations, however, warrant closer monitoring.

Patients on Central Nervous System Depressants

If you are also taking a benzodiazepine, a z-drug (zolpidem, eszopiclone), a sedating antihistamine, or gabapentinoids, the additive sedation from L-theanine becomes more relevant. A 2021 systematic review in Nutrients found that L-theanine at 200 to 400 mg produced clinically meaningful reductions in subjective anxiety scores (standardized mean difference: 0.31, 95% CI 0.01 to 0.61) [13]. Adding that anxiety reduction on top of other CNS depressants requires prescriber review.

Patients with Seizure Disorders

As noted above, both LDN and L-theanine have mild NMDA-modulating properties. Patients with a history of seizures should discuss this combination with their neurologist before starting, even though no case reports of seizure provocation from this combination exist in the published literature as of early 2025.

Pregnant or Breastfeeding Patients

L-theanine safety in pregnancy has not been established in human trials. LDN use in pregnancy is similarly unsupported by prospective data. Neither substance should be used during pregnancy without explicit physician guidance. The NIH Office of Dietary Supplements notes that data on L-theanine in pregnant or nursing women are insufficient to make a safety determination [14].

Patients with Hepatic Impairment

Naltrexone undergoes extensive hepatic metabolism [1]. In patients with significant liver disease, naltrexone clearance may be reduced and plasma levels may be higher than expected. While L-theanine does not affect hepatic enzymes, patients with impaired liver function should have their LDN dose reviewed by a physician before adding any supplement that could affect subjective CNS status.

What the Research Still Does Not Know

No randomized controlled trial has directly studied the combination of L-theanine and low-dose naltrexone in human subjects. The conclusion that "no pharmacokinetic interaction exists" rests on mechanistic reasoning from separate bodies of research, not from a head-to-head combination study. This is a common gap in supplement-drug interaction research.

A 2023 review in Frontiers in Pharmacology highlighted that fewer than 12% of commonly used dietary supplements have been evaluated in direct drug interaction studies using human pharmacokinetic endpoints [15]. L-theanine plus LDN falls squarely in that uninvestigated 88%.

The correct clinical interpretation: the available mechanistic and pharmacokinetic data do not predict a harmful interaction, but the absence of a dedicated combination trial means certainty is not possible. Prescriber disclosure remains the responsible baseline.

How to Discuss This with Your LDN Prescriber

Tell your prescriber the brand, dose, and timing of L-theanine you are considering. Most LDN-prescribing clinicians are familiar with L-theanine because it is one of the most commonly used supplements among their patient population. Bring a product label so the clinician can verify the dose and confirm there are no other active ingredients (some L-theanine products are formulated with GABA, 5-HTP, magnesium, or melatonin, each of which carries its own interaction profile with LDN).

Clinicians reviewing the LDN + L-theanine pairing should note that the 2021 LDN Research Trust consensus statement advises disclosing all supplements at each clinical visit because "even supplements with benign individual profiles may produce additive CNS effects when combined with LDN in certain patients" [16].

Monitoring Checklist After Starting Both

Once you and your prescriber agree to trial L-theanine alongside LDN, track the following for the first four weeks:

• Morning alertness on a 1 to 10 scale (to detect unexpected next-day sedation from evening L-theanine)
• Sleep quality (LDN often improves sleep; L-theanine taken at night may add to this)
• Subjective anxiety levels (the combination may reduce anxiety more than LDN alone)
• Any gastrointestinal symptoms (nausea is a known LDN side effect in the first two weeks; L-theanine is generally well-tolerated at 100 to 400 mg)
• Fibromyalgia or inflammation symptom scores if that is your LDN indication, to distinguish placebo-adjacent improvements from any genuine additive effect

A 2022 open-label cohort study of LDN in fibromyalgia patients (N=218) reported that 43% of participants were concurrently using at least one dietary supplement, and no significant adverse event attributable to supplement co-use was documented over 24 weeks of follow-up [17]. L-theanine was among the supplements in use, though the study was not powered to assess individual supplement interactions.